Advanced Medical Solutions Grp PLC
7 December 2000
ADVANCED MEDICAL SOLUTIONS SIGNS USA DEAL TO SELL
SPYROFLEXR BRAND TO AGS LABS INC.
Winsford, 7 December 2000: Advanced Medical Solutions Group plc announced
today that it has signed an agreement with AGS Laboratories Inc. of Texas
whereby AGS has taken over sole distribution for its SpyroflexR range of
consumer first aid dressings and has rights to acquire the associated
trademark.
The SpyroflexR brand name was acquired by Advanced Medical Solutions in 1999
and comprises a range of products for the treatment of cuts, grazes, minor
bleeding wounds and blisters based on proprietary polyurethane membrane
technology.
This range had been sold for a number of years into the US outdoor sports
market for climbers, runners and cyclists with AGS as the primary distributor.
In January it was also launched into the pharmacy first aid channel by
Advanced Medical Solutions via sales agents. Under this new deal, AGS will
now sell and distribute the range into both markets in the USA.
Advanced Medical Solutions retains the patents for the products and will
continue to develop and manufacture the complete product range. AGS will
build the brand and has the right to acquire the SpyroflexR trademark for a
total consideration of $450,000, subject to achieving minimum annual sales
volumes.
Commenting on the deal, Don Evans, Chief Executive of Advanced Medical
Solutions Group plc, said:
'We are delighted to have secured this deal and believe that AGS remains the
ideal partner for the SpyroflexR range of products in the United States. The
structure of the deal including the potential to acquire the SpyroflexR
trademark provides an incentive for AGS which we believe will ensure the
continued strength of our own order book going forward.'
Jim Tehan, President of AGS Inc. added:
'The SpyroflexR range of products has been extremely popular with our
customers and this deal provides us with the flexibility to further build the
brand in the USA. We look forward to maintaining our relationship with
Advanced Medical Solutions and taking advantage of further products which they
develop to accompany the current product offering.'
Enquiries:
Advanced Medical Solutions Group plc Tel: 01606 863500
Don Evans, Chief Executive
Mary Tavener, Finance Director
Graeme Brookes, Sales & Marketing Director
www.admedsol.com
Gavin Anderson & Company Tel: 0207 457 2345
Philip Ward / Charlotte Stone
AGS Inc. Tel: 001 972 579 3300
Jim Tehan, President
This press release includes forward-looking statements based on management's
current expectations. Such forward-looking statements refer to management's
plans and objectives for future operations, products and services. Factors
that could cause future results to differ materially from expectations
include, but are not limited to, the availability of resources, changes in
general economic and business conditions, government regulatory actions,
competition and general business, technical and other risks related to the
Company's business and operating environment.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.